Botulinum toxins for facial lines: A concise review

Dermatology and Therapy

Volumn 2, Issue 1, 2012, Pages 2-14

  Lowe, Nicholas J ^a   Lowe, Philippa ^b  

^a Cranley Clinic   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Axillary hyperhidrosis; Botulinum toxins; Combination treatment; Dermatology; Facial lines; Periocular muscles; Strabismus

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO;

AGING; DIPLOPIA; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRY EYE; DYSARTHRIA; DYSPHAGIA; DYSTONIA; FACE MUSCLE; HEADACHE; HUMAN; HYPERHIDROSIS; INCIDENCE; MOLECULAR WEIGHT; MUSCLE CONTRACTION; PARESTHESIA; PRIORITY JOURNAL; PTOSIS; QUANTITATIVE STUDY; REVIEW; SKIN BRUISING; SKINFOLD; STRABISMUS; WRINKLE;

EID: 84871141578     PISSN: None     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-012-0014-6     Document Type: Review

References (23)

1. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924-7.
2. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044-9.
3. Carruthers JD, Carruthers JA. Treatment of glabellar from lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17-21.
4. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: results of a doubleblind, placebo-controlled study. Plast Reconstr Surg. 1994;94:94-9.
5. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol. 1996;35:569-72.
6. Carruthers JA, Lowe NJ, Menter MA, for the BOTOX Glabellar Lines I Study Group, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-9.
7. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N, for the BOTOX Glabellar Lines II Study Group, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-98.
8. Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, for the Botox Facial Aesthetics Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31:257-62.
9. Flynn TC, Carruthers JA, Carruthers JA, Clark RE II. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. Dermatol Surg. 2003;29:943-50.
10. Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Moore D. Botulinum toxin types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther. 2002;4:15-8.
11. Lowe NJ, Campanati A, Bodokh J, et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol. 2004;151:1115-22.
12. Heckmann M, Hyperhidrosis Study Group. Low dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, openlabel study. Arch Dermatol. 2005;141:1255-9.
13. Kranz G, Paul A, Voller B, et al. Long-term efficacy and potencies of botulinum toxin A and B: A randomized, double-blind study. Br J Dermatol. 2011;164:176-81.
14. Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plastic Reconstr Surg. 1999;103: 645-52.
15. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51:223-33.
16. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum type A for the treatment of glabellar lines: a double-blind randomized study. J Am Acad Dermatol. 2006;55:975-80.
17. Lowe NJ. When and how to combine treatments. In: Lowe NJ, Carruthers A, Carruthers J, et al., editors. Textbook of facial rejuvenation. London: Informa Healthcare; 2002:322-5.
18. Yamauchi PS, Lask G, Lowe NJ. Botulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing. J Cosmet Laser Ther. 2004;6:145-8.
19. Carruthers J, Carruthers A, Maberly D. Deep resting glabellar rhytides respond to BTX-A and Hylan B. Dermatol Surg. 2003;29:539-44.
20. Lowe NJ, Shah A, Lowe PL, Patnaik R. Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines. J Cosmet Laser Ther. 2010;12:106-11.
21. Nettar KD, Yu KC, Bapna S, Boscardin J, Maas CS. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg. 2011; 13:380-6.
22. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010; 36(Suppl 4):2146-54.
23. Brandt F, O'Connell C, Cazzaniga A, Waugh JM. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg. 2010;36:2111-8.